Policies, codes and standards
Information regarding our codes of conduct, public policies, and other reporting information.
Our core values of transparency, respect for people, integrity, and patient-focus guide us in everything we do. And our employees, our partners and our suppliers are expected to adhere to the strict codes of ethical conduct that support these values.
GSK’s commitment to disease prevention and advancing quality care
The U.S. pharmaceutical industry relies upon a market-based healthcare system that balances patient access, quality of care, and affordability, while encouraging competition to develop innovative treatments that improve patient health and lower healthcare spending over time.
GSK’s guiding principles include Advancing Patient Access and Improving Healthcare Quality. Our scientists work tirelessly to develop new vaccines and medicines to prevent or treat disease. We also work hard to ensure that our vaccines and medicines are covered by healthcare plans and through our patient assistance programs. Visit GSKforYou for more information about our U.S. prescription access programs.
We also aim to improve healthcare quality by contributing to the development of quality measures used by healthcare systems to help drive the most impactful healthcare outcomes. These quality measures help set the standards for our U.S. healthcare system as well as for new target vaccines and treatments.
GSK and working with the healthcare and nonprofit communities
No researcher—or healthcare company—works in a silo. We need each other, and many others, to help move healthcare forward.
For our part, we work with members of the medical and research communities who are close to patients and understand both diseases and treatments. This sharing of information is vital to our mission to help people do more, feel better and live longer.
Working with members of the healthcare community—treating physicians, clinical researchers, patients, and professional associations and advocacy groups, etc.—may involve compensation for work performed, reimbursement for travel expenses, a charitable donation, or a grant.
Learn more about our work with the healthcare and nonprofit communities.
GSK and the environment
GSK has demonstrated a strong commitment to the safe and proper use and disposal of our self-injectable medications. Patient safety and needle stick injury prevention are given serious consideration in product development. In fact, inherent in the design of our injectable products, we use safe needle technology to shield the sharps and provide, at a minimum, approved sharps containers for home generated sharps waste materials.
- GlaxoSmithKline Safe Needle Disposal Plan - California (PDF)
- GlaxoSmithKline Safe Needle Disposal Plan - Minnesota (PDF)
GSK and post-marketing research
We don’t stop researching a medicine once it is approved by regulatory authorities. “Post-marketing” research may generate important new safety and efficacy information. We want to openly share information about the status of post-marketing research that we are obligated to conduct either to fulfill legal or regulatory requirements (post-marketing requirements or PMRs) or to carry out agreements with the US Food and Drug Administration (post-marketing commitments or PMCs).
Manufacturers of medicines are required to report to the FDA annually on the status of PMRs and PMCs and FDA is required to make certain information available to the public. Additional background on PMRs and PMCs is available on the FDA’s web site.
We will post information on our own website about PMRs and PMCs for U.S. marketed drugs and vaccines on a quarterly basis. Our quarterly updates will tend to reflect new developments more quickly than FDA’s website, which is based on required submissions of information from manufacturers that take place annually rather than quarterly.
Information will include the nature and status of the PMRs and PMCs. Like the FDA website, the GSK site will not include commitments with proprietary information (such as those to evaluate chemistry or manufacturing and control issues).
When a GSK-sponsored interventional clinical research study is completed, we are committed to seeking publication of the results in a peer-reviewed journal. Whether or not it actually gets published, we make available a summary of the results on our website the GSK Clinical Study Register. The Register provides an easily accessible repository of summary results from across the range of GSK-sponsored clinical studies, including not only all GSK-sponsored interventional clinical trials but also certain GSK-sponsored non-interventional studies (observational studies, health outcomes studies, epidemiology studies, and meta-analyses and pooled analyses).
GSK and supply chain and human rights
Patients and consumers rely on us to provide an uninterrupted supply of medicines and products, manufactured to the highest-quality standards.
An effective and responsibly managed supply and distribution system is essential for us to get high-quality products to the right places at the right time. If we don’t do this, people’s health may suffer and their lives may even be at risk. To protect the interests of our patients and consumers, we aim to work with responsible suppliers who meet the same quality, social and environmental standards as GSK.
We are committed to upholding the UN Universal Declaration of Human Rights, the OECD Guidelines for Multinational Enterprises and the core labor standards set out by the International Labour Organization (ILO). We are also a signatory to the UN Global Compact, a voluntary global standard on human rights, labor, the environment and anti-corruption.
We believe governments have a responsibility to define and enforce a legal framework for human rights in accordance with international laws and agreements. Businesses also have responsibilities. We have direct control over human rights in our own operations and aim to act responsibly across all our spheres of influence which includes our employees, suppliers, local communities and society more broadly.
Read our human rights statement (PDF).
California Transparency in Supply Chains Act
We believe that our policies and processes to ensure respect for human rights align with the requirements of the US California Transparency in Supply Chains Act, which came into effect at the beginning of 2012.
Zebulon, NC Contractor Safety Manual
At GSK, we place a great emphasis on safety in the workplace. The Zebulon Contractor Safety Manual (PDF) contains policies and procedures applicable to all contractors and contract employees regarding environment health & safety responsibilities on GlaxoSmithKline Zebulon premises and for work performed for GSK Zebulon.
LGBT Rights in the United States
GSK supports the advancement of human and civil rights for the Lesbian, Gay, Bisexual, and Transgender (LGBT) community, in furtherance of the values of equality and inclusion that GSK espouses for all of its employees.
Read our LGBT rights statement (PDF).
GSK Code of contact
Anti-Bribery and Corruption (ABAC) Program
The Anti-Bribery and Corruption (ABAC) Program is part of GSK’s response to the threat and risk of bribery and corruption. The program includes the ABAC Handbook, which has been designed to assist internal and external parties understand corruption risk and identify people’s responsibilities to actively combat both real and perceived corruption.
Anti-Bribery and Corruption Program Third Party Guidelines
Third Party Guidelines are provided to all third parties that GSK engages with in order to make them aware of our anti-bribery and corruption policies and what we expect from them as our business partners
GSK and business integrity
Visit our global site for a complete list of global policies